Skip to main content

Table 1 Clinical situations and the characteristics of the CAR T cells used to treat the 134 CLL patients reported to date

From: State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

  Clinical context CAR T characteristics Efficacy Toxicity
Reference/year Number of CLL patients Clinical situation Prior ttmt with ibrutinib Prior ttmt with venetoclax TP53 alterations Complex karyotype Targeted Ag Co-stimulation Cell source Lymphodepletion Treatment combination Responses CRS all grades N (%) CRES all grades N (%) Toxcity-related mortality
[8] / 2011 1 R/R 0 0 1/1 0 CD19 4-1BB Autologous P + C None CR 1 (100) 0 0
[9] / 2011 8 R/R 0 0 2/8 1/8 CD19 CD28 Autologous None or C None 3/8 SD 8 (100) 0 1(13)
[10] / 2011 3 R/R 0 0 2/3 0 CD19 4-1BB Autologous B + R or P + C None 3/3 ORR
2/3 CR
3 (100) 0 0
[11] / 2012 4 R/R 0 0 ND ND CD19 CD28 Autologous F + C IL2 IV for 5 d 3/4 ORR
1 CR
4 (100) 0 0
[12] / 2013 4
2 Richter
Recurrence after allogeneic treatment 0 0 2/4 ND CD19 CD28 Allogeneic None None 1/4 ORR
1 PR
1 SD
ND ND 0
[13] / 2015 5
1 Richter
R/R ND ND ND ND CD19 CD28 Autologous F + C None 5/5 ORR
3 CR 2 PR
3 (60) 1 (20) 0
[14] / 2015 14 R/R 1/14 0 6/14 ND CD19 4-1BB Autologous B or P+ C or F + C None 8/14 ORR (57%)
4/14 CR (28%)
4/14 PR (28%)
4 MRD neg
9 (64) 5 (36) 0
[15] / 2016 3 R/R 3/3 0 3/3 2/3 CD19 4-1BB Autologous ND Ibrutinib stopped just before leukapheresis 3/3 ORR
1 CR 2 PR
ND ND ND
[16] / 2016 5 Recurrence after allogeneic treatment ND ND ND ND CD19 CD28 Allogeneic None None 2/5 ORR
1 CR
1 PR
4 (80) 0 0
[17] / 2016 2 R/R 0 0 ND ND Kappa CD28 Autologous None None 0 ORR
1 SD
ND ND ND
[18] / 2017 24
5 Richter
R/R post-ibrutinib
25% post venetoclax
24/24 6/24 23/24 16/24 CD19 4-1BB Autologous F + C mostly, or F or C None 71% ORR
21% CR
43% PR
58% MRD neg
20 (83) 8 (33) 1 (4)
[19] / 2018 8 1st line P + FC 0 0 0 0 CD19 CD28 Autologous C None 3/8 ORR (38%)
2/8 CR
4 (50) 0 0
[20] / 2018 19
4 Richter
R/R post-ibrutinib 19/19 11/19 14/19 14/19 CD19 4-1BB Autologous F + C Concomitant ibrutinib 15/18 ORR (83%)
11/13 CR BM with MRD neg
14 (74) 6 (32) 1 (5)
[21] / 2018 19 R/R ×14
+1st line ibrutinib ×5
5 in 1st line 0 11/19 ND CD19 4-1BB Autologous ND“chemotherapy” Concomitant ibrutinib 10/11 ORR
94 CR BM with
78% MRD neg
18 (95) 5 (26) 0
[22] / 2018 16 R/R post-ibrutinib 16/16 8/16 10/16 8/16 CD19 4-1BB Autologous F + C None 81.3% ORR
7 CR
6 PR
12 (75) 1 (6) 0
  1. The patient from reference [8] is also reported in reference [10] and the 3 patients from the reference [10] are also reported in reference [14]. One patient reported in reference [11] is also reported in reference [13]
  2. R/R relapse/refractory disease, ORR overall response rate, CR complete response, PR partial response, SD stable disease, ND no data, Ttmt treatment, IV intravenous, C cyclophosphamide, B bendamustine, R rituximab, P pentostatin, F fludarabine, CRS cytokine release syndrome, CRES CAR T cell-related encephalopathy syndrome